Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
企業コードASBP
会社名Aspire Biopharma Holdings Inc
上場日Feb 18, 2022
最高経営責任者「CEO」- -
従業員数- -
証券種類Ordinary Share
決算期末Feb 18
本社所在地194 Candelaro Drive, #233
都市HUMACAO
証券取引所NASDAQ OMX - NASDAQ BASIC
国Puerto Rico
郵便番号00791
電話番号
ウェブサイト
企業コードASBP
上場日Feb 18, 2022
最高経営責任者「CEO」- -
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし